Cure8 news brief
Perianal fistulas are a serious, hard-to-treat complication of Crohn’s disease. Evidence that guselkumab (Tremfya) can sustain fistula remission through 48 weeks could expand treatment options for people with fistulizing Crohn’s disease.
Adults with Crohn’s disease (especially those with perianal fistulas), IBD clinicians, and researchers focused on fistulizing disease or biologic therapies.
The FUZION trial evaluated guselkumab (Tremfya) in patients with perianal fistulizing Crohn’s disease and measured combined fistula remission using clinical and radiologic assessments.
At Week 24, Tremfya showed a statistically evaluated benefit versus placebo; the company reports that remission rates were maintained or improved at Week 48 with both 100 mg every eight weeks and a higher maintenance 200 mg every four weeks regimen.
The longer-term safety through 48 weeks was consistent with the established profile and no new safety concerns were reported in the company release.
The reported results are from a company press release presented at UEG Week and describe extension outcomes through 48 weeks; the 48-week comparisons reported here do not include a new placebo-controlled comparison in the company summary. The study population included patients with prior biologic exposure as well as biologic-naïve patients.
Results were presented by the company at UEG Week and come from the Phase 3 FUZION trial. The 48-week figures reported do not include a new placebo-controlled comparison in the company summary; await full peer-reviewed publication or regulatory disclosures for complete data and safety details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
